Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Compare fund families based on index fund history and identify which has demonstrated the strongest long-term performance and stability.
28,115 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Volatility is shaping a smarter approach to investing. Discover three growth stocks worth $5,000 and how to build a f...
Bitcoin shows signs of a distribution phase as profit-taking rises and ETF outflows weigh on price. On-chain metrics ...
Micron Technology rides the AI memory wave, but a blowout earnings report invites questions. This guide breaks down t...
As institutional buyers step into Openlane, individual investors gain a front-row seat to a digitized used-vehicle ma...
This satellite data stock has pulled back after a scorching rally. In this guide, you’ll learn what powers its busine...
A leading tech investor envisions a future where AI-enabled labor trims traditional work yet expands access to essent...
One stock that's more than doubled in three years has turned heads in growth-focused portfolios. This article dives i...
BioCryst faces a pivotal year. This practical guide breaks down what biocryst (bcrx) 2026 earnings could mean for inv...
When executives cash out after a stock's triple-digit run, it can raise questions for investors. This guide explains ...
Gabelli’s team signals a long-running capex wave in defense, benefiting both the big primes and smaller suppliers. Al...
Policy makers and tech leaders converge to treat China as a shared risk in AI leadership, signaling potential shifts ...